The Long Road: Treatment, Recovery, and Lasting Health Effects of COVID-19
Once you register for the course, you will have 30 days from the date of enrollment to complete the course. The date your access expires will be indicated in the Course Summary box on this webpage.
"#CovidVaccine! I got it for my family, my team of coworkers, but most importantly for my patients. The ones who I’ve talked to while sedated, held the iPad for so loved ones could say goodbye, and held their hand as they have slipped away from this world. #COVID #MaskUp"
- Nikki LaFratte, BSN, RN, CCRN, Speaker
After a steady decline since January 2021, COVID-19 cases and hospitalizations in Iowa have risen dramatically since July 2021. Resources and guidelines related to COVID-19 are constantly changing and new scientific evidence is emerging on a daily basis. In late July 2021, the Centers for Disease Control and Prevention released updated guidance related to the newly discovered Delta variant, which has added another level of uncertainty for healthcare providers and patients alike. Additionally, in August 2021, the U.S. Food and Drug Administration amended the emergency use authorizations for both the Pfizer-BioNTech and Moderna COVID-19 vaccines to allow for the administration of a third dose for certain individuals. This constant flow of information can make it difficult for healthcare providers to keep up with the current scientific environment.
Discovery of new evidence also contributes to changes in treatment recommendations in hopes of improving patient outcomes. Although most individuals that contract COVID-19 recover easily and have minimal impact to their overall health, some people experience a wide range of lasting conditions that may extend well beyond four weeks from their initial diagnosis. These lasting health effects vary in symptomology and duration, and can be easily missed or mistaken for another condition. It is essential that healthcare providers stay abreast of the current scientific evidence and acknowledge the role of treatment and recovery in the long-term wellbeing of their patients.
- Empathize with the patient journey, including fears, virtual family interactions, and recovering from COVID-19 infection.
- List three factors that are contributing to the current rise in COVID-19 cases and hospitalizations in Iowa.
- Compare and contrast symptomology and treatment recommendations related to the Delta variant of the virus.
- List the primary differences between a patient that is diagnosed with COVID-19 versus other respiratory infections.
- Describe the patient populations that may benefit from a third dose of the COVID-19 vaccine.
Recording date: October 14, 2021
Date of original release: October 20, 2021
Most recent review/update: October 20, 2021
Termination date: October 19, 2024
Aneesa Afroze, MD, MPH, FACP, AAHIVS, CTH
Infectious Disease Consultant, Antimicrobial Stewardship Program Director, and Medical Staff President, MercyOne Des Moines Pulmonary & Infectious Disease Care
Nikki LaFratte, BSN, RN, CCRN
Critical Care Nurse, MercyOne Des Moines and Assistant Professor, Mercy College of Health Sciences
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS). Des Moines University (DMU) is accredited by the IMS to provide continuing medical education for physicians. DMU designates this enduring materials activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this activity for a maximum of 1.0 AOA Category 2-B credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This activity has been reviewed and approved for 1.0 continuing education contact hour(s). No partial credit awarded.
- Other Healthcare Professionals: This enduring materials activity is designated for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
No ineligible company provided financial support for this continuing education activity.
The planning committee member(s) and speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director.
Relevant to the content of this educational activity, the following individual(s) have no conflict(s) with ineligible companies to disclose.
- Aneesa Afroze, MD, MPH, FACP, AAHIVS, CTH - Speaker
- Phill Butler - Speaker
- Nikki LaFratte, BSN, RN, CCRN - Speaker
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 1.00 AMA PRA Category 1 Credits™
- 1.00 AOA Category 2B
- 1.00 CE Contact Hour(s)
- 1.00 IBON